- Home
- SITC vs CHRS Comparison
SITC vs CHRS Comparison
Compare SITC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | CHRS |
|---|---|---|
| Founded | 1965 | 2010 |
| Country | United States | United States |
| Employees | 155 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.5M | 291.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SITC | CHRS |
|---|---|---|
| Price | $5.40 | $1.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $7.75 | $5.51 |
| AVG Volume (30 Days) | 989.7K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 125.00% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | N/A | ★ 1.43 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | $12.09 | ★ $1.21 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.24 | $0.72 |
| 52 Week High | $12.74 | $2.62 |
Technical Indicators
Market Signals| Indicator | SITC | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 35.35 | 51.89 |
| Support Level | N/A | $1.55 |
| Resistance Level | $6.57 | $1.78 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 27.59 | 63.64 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.